features: Biology

Amyloid in Alzheimer’s disease: toxic accumulation or loss of normal function?

New data published in the Journal of Alzheimer’s disease suggest that the loss of soluble Aβ42 predicts cognitive decline better…

Breakthrough in Alzheimer’s disease diagnosis: FDA authorizes diagnostic test for β-amyloid plaques

The U.S. Food and Drug Administration (FDA) has authorized the marketing of the Fujirebio’s Lumipulse G β-Amyloid Ratio (1-42/1-40) in…

New risk genes associated with Alzheimer’s disease identified

An exciting study published in Nature Genetics has doubled the number of genetic loci known to associate with Alzheimer’s disease,…

Highlights from ARUK 2022

The Alzheimer’s Research UK Conference was held in Brighton, UK, on 1-2 March 2022. Leading experts discussed the key topics…

The Phase II/III GAIN Trial: atuzaginstat for mild-moderate Alzheimer’s disease

Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…